Key facts
- The increasing popularity of GLP-1 weight loss drugs like Ozempic is impacting the fine dining industry.
- Restaurants are observing diners consuming significantly less food, leading to untouched courses.
- Some establishments, like Heston Blumenthal's The Fat Duck, are introducing 'mindful experiences' with reduced tasting menus.
- Restaurant staff are being trained to offer discreet solutions, such as skipping courses or boxing up uneaten food.
- Diners' use of these drugs is a growing trend, with some announcing it openly and others being more secretive.
The rise of GLP-1 weight loss drugs, commonly known as Ozempic and Wegovy, is presenting a new challenge for the fine dining industry. These medications suppress appetite, leading diners to consume less food, which conflicts with the traditional expectations of high-end restaurants.
Chefs and restaurateurs are grappling with how to adapt to this trend. Heston Blumenthal, chef at the three-Michelin-starred The Fat Duck, has introduced a 'Mindful Experience' tasting menu, acknowledging the impact of these drugs after experiencing reduced hunger himself. He expressed concern that such medications could negatively affect the restaurant industry.
This shift also necessitates changes in dining etiquette. Top UK sommelier Jonathan Kleeman notes that chefs are often concerned when plates return with food left on them. Waitstaff are now being trained to recognize and accommodate diners with smaller appetites, offering to skip courses or even box up uneaten portions, a practice that is an imperfect but necessary solution in these changing times.
Some diners are openly discussing their use of these weight loss drugs, with Victor Garvey, chef at the Michelin-starred Sola, observing a surprising lack of shame. This contrasts with the more discreet approach of others, highlighting a new social dynamic around appetite suppressants.